2026-04-29T00:59:45Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/186972024-09-21T21:44:22Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Kanesvaran, R author Castro, E author Wong, A author Fizazi, K author Chua, M L K author Zhu, Y author Malhotra, H author Miura, Y author Lee, J L author Chong, F L T author Pu, Y-S author Yen, C-C author Saad, M author Lee, H J author Kitamura, H author Prabhash, K author Zou, Q author Curigliano, G author Poon, E author Choo, S P author Peters, S author Lim, E author Yoshino, T author Pentheroudakis, G author 2022-07-04 The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of prostate cancer was published in 2020. It was therefore decided, by both the ESMO and the Singapore Society of Oncology (SSO), to convene a special, virtual guidelines meeting in November 2021 to adapt the ESMO 2020 guidelines to take into account the differences associated with the treatment of prostate cancer in Asia. These guidelines represent the consensus opinions reached by experts in the treatment of patients with prostate cancer representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with prostate cancer across the different regions of Asia. http://hdl.handle.net/10668/22219 http://hdl.handle.net/20.500.12105/18697 35797737 10.1016/j.esmoop.2022.100518 2059-7029 ESMO open ESMO Pan-Asian guidelines prostate cancer treatment Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.